J&J/Caprion
This article was originally published in The Gray Sheet
Executive Summary
In vitro blood test for the human equivalent of mad cow disease, Creutzfeldt-Jacob disease (CJD), will be developed by the Ortho-Clinical Diagnostics unit of Johnson & Johnson under an exclusive, worldwide license agreement with Caprion Pharmaceuticals. The test will be based on prion technologies related to the monoclonal antibodies for CJD. Roche and Prionics also inked an agreement earlier this year for development of a CJD blood test (1"The Gray Sheet" Jan. 29, 2001, In Brief)...
You may also be interested in...
Abbott, ProMetic Pacts With Red Cross Cover Blood Screening, TSE Removal
The American Red Cross will retain a 74% equity stake in a joint venture with ProMetic Life Sciences to develop systems for detection and removal of transmissible spongiform encephalopathy (TSE) pathogens from blood and blood components
Roche Diagnostics/Prionics
Firms will collaborate in development of a blood test for the detection of Creutzfeldt-Jacob disease in humans under an agreement announced Jan. 24. CJD is related to bovine spongiform encephalopathy (BSE), or "mad cow disease." The deal also calls for Roche to distribute the Prionics-Check rapid test for the detection of BSE in dead cattle effective Feb. 1
Investors Go Berserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.